---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-004514"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:42:07.267253+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M

## Summary
- Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).
- Jakafi net revs Q4 $773M (+11% YoY), FY $2.79B (+8%); Opzelura Q4 $162M (+48%), FY $508M (+50%).
- FY2025 guidance: Jakafi $2,925-2,975M; Opzelura $630-670M; other oncology $415-455M.
- Pipeline catalysts: Niktimvo launched; ruxolitinib XR bioequivalence met, submission by year-end 2025; four pivotal readouts in 2025.
- Cash and securities $2.2B at Dec 31, 2024, down from $3.7B due to $2B share repurchase and $783M Escient acquisition.

## SEC filing metadata
- accession: 0001628280-25-004514
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/0001628280-25-004514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-20250210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-004514
- JSON: https://secwatch.observer/filing/0001628280-25-004514.json
- Plain text: https://secwatch.observer/filing/0001628280-25-004514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.